Protagonist Therapeutics (PTGX) CEO Dinesh Patel discusses the company's peptide technology platform and its development of orally delivered alternatives to injectable therapies. He highlights partnerships with Johnson & Johnson (JNJ) and Takeda (TAK), while outlining opportunities in obesity, autoimmune diseases and rare blood disorders.